Text and Data Mining valid from 2018-07-24
Received: 20 April 2018
Accepted: 16 July 2018
First Online: 24 July 2018
Change Date: 3 September 2018
Change Type: Correction
Change Details: Ad-HBV is a product (T101) aiming to treat chronic HBV firstly developed by Transgene S.A., France then by Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China in China.
: The animal experiments were conducted in a GLP-compliant and AAALAC-accredited laboratory (Jiangsu Tripod Preclinical Research Laboratories Co., Ltd., Nanjing, China), and all study protocols were approved by the testing facility’s Institutional Animal Care and Use Committee.
: The authors declare that there are no competing interest regarding the publication of this paper.
: Not applicable.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.